Pemigatinib is produced by Daxiong or Lucius

Pemigatinib (Pemigatinib) is an FGFR inhibitor developed by Incyte and is an original drug. In China and some countries, "Dabotan" is usually used as the trade name. With the gradual liberalization of global drug policies and changes in patent status, generic versions produced by different pharmaceutical companies have appeared in many countries, including Laos' Bear Pharmaceuticals (Bear) and Laos' Lucius Pharmaceuticals (Lucius). Therefore, many cholangiocarcinomapatients will pay attention to practical issues such as "Which manufacturer is more reliable" and "Whether the ingredients of generic drugs are consistent" during consultation.

Overseas, some countries allow the production of generic pemetinib drugs, which require consistent ingredients, matching specifications and compliance with local GMP standards. GMP standards. For example, Lucius Pharmaceuticals’ 4.5mg*14 tablets are more common, and its selling price is greatly affected by exchange rates and local policies. In these regions, generic drugs often serve as lower-cost alternatives, especially for patients who cannot afford brand-name drugs.

It should be emphasized that although the ingredients of generic drugs are basically the same as those of original drugs, there are still differences between the two in terms of production process, impurity control, and depth of stability research. Original drugs have a complete R&D and verification system, while generic drugs rely more on proof of equivalence. Therefore, regulatory intensity is different in different countries, and product quality may also vary. When choosing, patients should pay more attention to whether the source is legitimate and whether it has quality certification, rather than just comparing brands.

The products of Big Bear and Lucius have a certain degree of circulation abroad, but before choosing generic drugs, you should make a comprehensive judgment based on your doctor's advice, the reliability of the source, and your own situation. Formal channels and quality traceability are always the first prerequisites to avoid choosing non-standard products due to low prices. If the original drug is available, it is still recommended to give priority to the more fully regulated version.

Reference materials:https://go.drugbank.com/drugs/DB15102